CliffBio
biologic

Actemra

tocilizumab

Loss of exclusivityOctober 2025projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameActemra
Active ingredienttocilizumab
Strength162MG/0.9ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2013
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Actemra patent cliff — loss of exclusivity October 2025 | CliffBio